Related references
Note: Only part of the references are listed.Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling
Annette S. Little et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation
Liqiang Xi et al.
BLOOD (2012)
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling
Michael Roering et al.
EMBO JOURNAL (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
F. Xing et al.
ONCOGENE (2012)
Targeting the RAS pathway in melanoma
Zhenyu Ji et al.
TRENDS IN MOLECULAR MEDICINE (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Inna V. Fedorenko et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi et al.
CANCER RESEARCH (2011)
Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation
Huisheng Wang et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Biology using engineering tools The negative feedback amplifier
Marc R. Birtwistle et al.
CELL CYCLE (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Oncogenic Ras-Induced Expression of Noxa and Beclin-1 Promotes Autophagic Cell Death and Limits Clonogenic Survival
Mohamed Elgendy et al.
MOLECULAR CELL (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
BRAF Mutations in Hairy-Cell Leukemia
Enrico Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Maurizio Scaltriti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
Annette S. Little et al.
SCIENCE SIGNALING (2011)
Regulation of cyclin D1 gene expression
Ini-Isabee Witzel et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
Ensar Halilovic et al.
CANCER RESEARCH (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a
Linda A. S. Carragher et al.
EMBO MOLECULAR MEDICINE (2010)
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Daniel A. Ritt et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
D. Ercan et al.
ONCOGENE (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
Oliver E. Sturm et al.
SCIENCE SIGNALING (2010)
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
Ryan B. Corcoran et al.
SCIENCE SIGNALING (2010)
Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Steven Whittaker et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
Jieru Meng et al.
CANCER BIOLOGY & THERAPY (2009)
Tumour cell survival signalling by the ERK1/2 pathway
K. Balmanno et al.
CELL DEATH AND DIFFERENTIATION (2009)
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Peter S. Hammerman et al.
CLINICAL CANCER RESEARCH (2009)
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
Dragana Milojkovic et al.
CLINICAL CANCER RESEARCH (2009)
Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics
Annette S. Gillings et al.
FEBS JOURNAL (2009)
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERKI/2 signalling and/or strong P13K signalling in colorectal cancer cell lines
Kathryn Balmanno et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Oncogenic Activating Mutations Are Associated with Local Copy Gain
Barmak Modrek et al.
MOLECULAR CANCER RESEARCH (2009)
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
Junichi Soh et al.
PLOS ONE (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling
Xin Li et al.
CELLULAR SIGNALLING (2008)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Jeffrey A. Engelman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Ras oncogenes: split personalities
Antoine E. Karnoub et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway:: genotype-phenotype relationships and overlap with Costello syndrome
Caroline Nava et al.
JOURNAL OF MEDICAL GENETICS (2007)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
S. Meloche et al.
ONCOGENE (2007)
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases
D. M. Owens et al.
ONCOGENE (2007)
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome
P Rodriguez-Viciana et al.
SCIENCE (2006)
The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions
S Yoon et al.
GROWTH FACTORS (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
JF Ohren et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2004)
Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352
AM Delaney et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Analysis of the transcriptional program induced by Raf in epithelial cells
A Schulze et al.
GENES & DEVELOPMENT (2001)
Share Paper
